Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)

被引：0
|
作者：
Perol, M. [1 ]
Sebastian, M. [2 ]
Barlesi, F. [3 ,4 ]
Schumann, C. [5 ,6 ]
Reynaud, D. [7 ]
Waldenberger, D. [8 ]
Lee, A. [9 ]
Varol, N. [9 ]
Penrod, J. R. [10 ]
Brellier, F. [11 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] Johannes Wolfgang Goethe Univ, Dept Hemat Med Oncol, Univ Klinikum Frankfurt, Frankfurt, Germany
[3] Paris Saclay Inst, Dept Med, Villejuif, France
[4] Gustave Roussy, Villejuif, France
[5] Klinikverbund Allgaeu gGmbH, Klin Pneumol Thoraxonkol Schlaf & Beamtungsmed, Kempten, Germany
[6] Klinikverbund Allgaeu gGmbH, Klin Pneumol Thoraxonkol Schlaf & Beamtungsmed, Immenstadt, Germany
[7] Bristol Myers Squibb, Med Oncol, Rueil Malmaison, France
[8] Bristol Myers Squibb GmbH & Co, Med Oncol, Munich, Germany
[9] Bristol Myers Squibb, WorldWide HEOR, Uxbridge, Middx, England
[10] Bristol Myers Squibb, WorldWide HEOR, Princeton, NJ USA
[11] Bristol Myers Squibb, Ctr Observat Res & Data Sci, Uxbridge, Middx, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2486
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1455P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC).
    Ma, Meng
    Zhou, Xiang
    Goldsweig, Howard
    Hahner, Nicholas
    Han, Dianwei
    Dietz, Matthew
    Jones, Scott
    Mullaney, Tommy
    Redfern, Arielle
    Jappe, Whitney
    Liu, Zongzhi
    Yadav, Kamlesh
    Zimmerman, Michelle
    Prentice, Tony
    Pan, Qi
    Hirsch, Fred R.
    Oh, William K.
    Schadt, Eric E.
    Li, Dan
    Chen, Rong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Real-World Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US
    Nadler, E.
    Chang, J.
    Zhang, X.
    Aguilar, K.
    Zhou, J.
    Arondekar, B.
    Pawar, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S38 - S39
  • [3] Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.
    Rivera, Donna R. R.
    Lasiter, Laura
    Christian, Jennifer
    Enewold, Lindsey
    Espirito, Janet L.
    Hansen, Eric
    Henk, Henry J.
    Kushi, Lawrence H.
    Lane, Daniel
    Natanzon, Yanina
    Benito, Ruth Pe
    Rasmussen, Erik
    Robert, Nicholas J.
    Stewart, Mark
    Sweetnam, Connor
    Tymejczyk, Olga
    Valice, Emily
    Wagner, Joseph
    Zander, Alia
    Allen, Jeff
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results
    Godbert, B.
    Gobbini, E.
    Zysman, M.
    Decroisette, C.
    Lena, H.
    Moro-Sibilot, D.
    Guisier, F.
    Egenod, T.
    Couraud, S.
    Brellier, F.
    Fleuriet, A.
    Khalife, Y.
    Girard, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S838 - S839
  • [6] Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies.
    Lu, Michael
    Sadetsky, Natalia
    Lambert, Peter
    Whipple, Sam
    Taylor, Michael Dennis
    Riehl, Todd
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting
    Assie, J.
    Cotte, F.
    Levra, M. Giaj
    Calvet, C.
    Jolivel, R.
    Jouaneton, B.
    Gaudin, A.
    Grumberg, V.
    Chouaid, C.
    Corre, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S708 - S708
  • [8] IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
    Dixmier
    Asselain, B.
    Barlesi, F.
    Debieuvre, D.
    Valette, C. Audigier
    Groeschel, A.
    Guetz, S.
    Liersch, R.
    Moro-Sibilot, D.
    Mueller-Huesmann, H.
    Perol, M.
    Raspaud, C.
    Schulte, C.
    Schulz, H.
    Schumann, C.
    Allan, V.
    Calvet, C. Y.
    Rothnie, K. J.
    Wuensch, V.
    Sebastian, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 614 - 614
  • [9] Real-world data on nivolumab treatment of non-small cell lung cancer
    Brustugun, O. T.
    Sprauten, M.
    Helland, A.
    ACTA ONCOLOGICA, 2017, 56 (03) : 438 - 440
  • [10] A real-world prospective study of nivolumab (NIVO) in patients (pts) with pretreated advanced non-small cell lung cancer (aNSCLC) in Greece and Cyprus - Interim analysis results of LUCENCE study
    Charpidou, Andriani
    Mani, Maria
    Lampaki, Sofia
    Stournara, Lambrini
    Kotsakis, Athanasios
    Samantas, Epameinodas
    Grammatikou, Violeta
    Kentepozidis, Nikolaos
    Koumarianou, Anna
    Syrigos, Konstantinos
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
12345